Literature DB >> 25499481

VATS lobectomy has better perioperative outcomes than open lobectomy: CALGB 31001, an ancillary analysis of CALGB 140202 (Alliance).

Chukwumere E Nwogu1, Jonathan D'Cunha2, Herbert Pang3, Lin Gu3, Xiaofei Wang3, William G Richards4, Linda J Veit5, Todd L Demmy6, David J Sugarbaker4, Leslie J Kohman5, Scott J Swanson4.   

Abstract

BACKGROUND: The short-term superiority of video-assisted thoracoscopic surgery lobectomy compared with open lobectomy for early-stage lung cancer has been suggested by single-institution studies. Lack of equipoise limits the feasibility of a randomized study to confirm this. The hypothesis of this study (CALGB 31001) was that VATS lobectomy results in shorter length of hospital stay and fewer complications compared with open lobectomy in stages I and II non-small cell lung cancer in a multi-institutional setting.
METHODS: Five hundred nineteen patients whose tumors had been collected as part of CALGB 140202 (lung cancer tissue bank) were eligible. Propensity-scoring using age, race, sex, performance status, comorbidities, histology, tumor stage, and size as independent variables was used to create a 1:1 matched group of 175 pairs of patients. McNemar's test for binary variables and Wilcoxon signed-rank test for continuous variables were used to assess differences in length of hospital stay, complications, and discharge dispositions between the groups. Comparison of disease-free and overall survival between the two approaches was done using the log-rank test. Probability values of less than 0.05 were considered significant.
RESULTS: The matched data on length of hospital stay, complications, and discharge dispositions significantly favored the video-assisted thoracoscopic surgery group. There was no statistically significant difference in survival between the two approaches.
CONCLUSIONS: This multi-institutional study supports the assertion that thoracoscopic lobectomy results in shorter hospital length of stay, fewer perioperative complications, and greater likelihood of independent home discharge compared with open lobectomy for early-stage lung cancer. Survival was comparable between the two groups.
Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25499481      PMCID: PMC5616174          DOI: 10.1016/j.athoracsur.2014.09.018

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  17 in total

1.  Outcomes after lobectomy using thoracoscopy vs thoracotomy: a comparative effectiveness analysis utilizing the Nationwide Inpatient Sample database.

Authors:  Subroto Paul; Art Sedrakyan; Ya-Lin Chiu; Abu Nasar; Jeffrey L Port; Paul C Lee; Brendon M Stiles; Nasser K Altorki
Journal:  Eur J Cardiothorac Surg       Date:  2012-07-22       Impact factor: 4.191

2.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

3.  Minimally invasive cancer surgery improves patient survival rates through less perioperative immunosuppression.

Authors:  B A Whitson; J D'Cunha; M A Maddaus
Journal:  Med Hypotheses       Date:  2006-12-01       Impact factor: 1.538

4.  Is video-assisted lobectomy for non-small-cell lung cancer oncologically equivalent to open lobectomy?

Authors:  Waël C Hanna; Moira de Valence; Eshetu G Atenafu; Marcelo Cypel; Thomas K Waddell; Kazuhiro Yasufuku; Andrew Pierre; Marc De Perrot; Shaf Keshavjee; Gail E Darling
Journal:  Eur J Cardiothorac Surg       Date:  2013-01-08       Impact factor: 4.191

5.  Video-assisted thoracoscopic lobectomy is less costly and morbid than open lobectomy: a retrospective multiinstitutional database analysis.

Authors:  Scott J Swanson; Bryan F Meyers; Candace L Gunnarsson; Matthew Moore; John A Howington; Michael A Maddaus; Robert J McKenna; Daniel L Miller
Journal:  Ann Thorac Surg       Date:  2011-11-30       Impact factor: 4.330

6.  Video-assisted thoracic surgery versus open thoracotomy for non-small-cell lung cancer: a propensity score analysis based on a multi-institutional registry.

Authors:  Christopher Cao; Zhi-Hua Zhu; Tristan D Yan; Qun Wang; Gening Jiang; Lunxu Liu; Deruo Liu; Zheng Wang; Wenlong Shao; Deborah Black; Qian Zhao; Jianxing He
Journal:  Eur J Cardiothorac Surg       Date:  2013-08-15       Impact factor: 4.191

7.  Long-term survival after lobectomy for non-small cell lung cancer by video-assisted thoracic surgery versus thoracotomy.

Authors:  Paul C Lee; Abu Nasar; Jeffrey L Port; Subroto Paul; Brendon Stiles; Ya-Lin Chiu; Weston G Andrews; Nasser K Altorki
Journal:  Ann Thorac Surg       Date:  2013-07-16       Impact factor: 4.330

8.  Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors.

Authors:  Daniel J Boffa; Mark S Allen; Joshua D Grab; Henning A Gaissert; David H Harpole; Cameron D Wright
Journal:  J Thorac Cardiovasc Surg       Date:  2007-12-21       Impact factor: 5.209

Review 9.  Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy.

Authors:  Bryan A Whitson; Shawn S Groth; Susan J Duval; Scott J Swanson; Michael A Maddaus
Journal:  Ann Thorac Surg       Date:  2008-12       Impact factor: 4.330

10.  Thoracoscopic lobectomy versus open lobectomy in stage I non-small cell lung cancer: a meta-analysis.

Authors:  Yi-xin Cai; Xiang-ning Fu; Qin-zi Xu; Wei Sun; Ni Zhang
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

View more
  63 in total

Review 1.  Video-assisted thoracoscopic surgery for complex mediastinal mass resections.

Authors:  M Blair Marshall; Lorenzo DeMarchi; Dominic A Emerson; Matthew L Holzner
Journal:  Ann Cardiothorac Surg       Date:  2015-11

2.  Salvage video-assisted thoracoscopic lobectomy for isolated local relapse after stereotactic body radiotherapy for early stage non-small cell lung cancer: technical aspects and perioperative management.

Authors:  Masatsugu Hamaji; Toyofumi-Fengshi Chen-Yoshikawa; Yukinori Matsuo; Hideki Motoyama; Kyoko Hijiya; Toshi Menju; Akihiro Aoyama; Toshihiko Sato; Makoto Sonobe; Hiroshi Date
Journal:  J Vis Surg       Date:  2017-06-22

3.  Single-direction thoracoscopic lobectomy: a step in the right direction.

Authors:  John S Young; Paul C Lee
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

Review 4.  Updates on Minimally Invasive Surgery in Non-Small Cell Lung Cancer.

Authors:  Norihiko Ikeda
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

5.  Stereotactic body radiotherapy for operable, early stage non-small cell lung cancer-let's all take a deep breath.

Authors:  Eric B Howell; Kathleen S Berfield; Douglas E Wood
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 6.  Video-assisted thoracoscopic surgery lobectomy for non-small cell lung cancer.

Authors:  Mingyon Mun; Masayuki Nakao; Yosuke Matsuura; Junji Ichinose; Ken Nakagawa; Sakae Okumura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-07-30

7.  A propensity matched comparison of effects between video assisted thoracoscopic single-port, two-port and three-port pulmonary resection on lung cancer.

Authors:  Ju-Wei Mu; Shu-Geng Gao; Qi Xue; You-Sheng Mao; Da-Li Wang; Jun Zhao; Yu-Shun Gao; Jin-Feng Huang; Jie He
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

8.  Crossing the bridge to VATS lobectomy.

Authors:  P Tcherveniakov; C Bogdan; N Chaudhuri
Journal:  Ann R Coll Surg Engl       Date:  2017-10-19       Impact factor: 1.891

Review 9.  Video-assisted thoracic surgery and open chest surgery in lung cancer treatment: present and future.

Authors:  Frank Detterbeck; Laureano Molins
Journal:  J Vis Surg       Date:  2016-12-06

Review 10.  Surgery versus stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer: less is not more.

Authors:  Abby White; Scott J Swanson
Journal:  J Thorac Dis       Date:  2016-04       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.